We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Imaging Reveals New Pathway for Anti-Cancer Treatment

By Biotechdaily staff writers
Posted on 22 May 2008
Researchers have discovered a possible new pathway for anti-tumor drugs to kill cancer cells and proposed how to improve the design of tiny drug-delivery particles for use in "nanomedicine.”

The synthetic "polymer micelles” are drug-delivery spheres 60-100 nanometers in diameter, or about 100 times smaller than a red blood cell. More...
The spheres contain drugs in their inner core and contain an outer shell made of a material called polyethylene glycol.

Researchers showed for the first time how this shell of polyethylene glycol latches onto the membranes of cancer cells, allowing fluorescent probes mimicking cancer drugs to enter the cancer cells, according to Dr. Ji-Xin Cheng, an assistant professor in the Weldon School of Biomedical Engineering and department of chemistry at Purdue University (West Lafayette, IN, USA). "This is an interesting new step in developing nanomedicine techniques in drug delivery,” he said.

The research is being led by Dr. Cheng and Dr. Kinam Park, a professor of biomedical engineering and pharmaceutics. New findings are detailed in two research articles. One study was published in the May 6, 2008 issue of the Proceedings of the [U.S.] National Academy of Sciences (PNAS), and another study was published in the May 2008 issue of the journal Langmuir.

The researchers utilized an imaging technique called Förster resonance energy transfer imaging (FRET) to make two significant findings: how fluorescent molecules mimicking the cancer drug paclitaxel enter tumor cells and how the micelles break down in the blood before they have an opportunity to deliver the drug to cancer cells.

An important feature of micelles is that they combine two types of polymers, one being hydrophobic, and the other hydrophilic, meaning they are either unable or able to mix with water. The hydrophobic core was loaded with a green dye and the hydrophilic part labeled with a red dye.

Experiments demonstrated that "core-loaded” fluorescent molecules mimicking the drug entered cancer cells within 15 minutes, suggesting a new drug-delivery pathway to destroy tumor cells, according to Dr. Cheng. The fluorescent probes produced a green color on the membranes and a yellowish color inside the cells. "So this technique provides a system to monitor in real time how well anti-cancer drug delivery is working,” Dr. Cheng said.

Further findings made by the investigators using mice demonstrate specifically how the drug is released prematurely in the blood. "We first proved that micelles are unstable in the blood, and then we answered why they don't remain intact,” Dr. Cheng said.

The researchers also propose a possible way to correct the problem by "crosslinking,” or reinforcing polymer strands in the micelles with chemical bonds made of two sulfur atoms. This reinforced structure might remain intact in the blood long enough to deliver the micelles to tumor sites, where they would biodegrade, according to Dr. Cheng.

The researchers are the first to use FRET to study drug release from polymer micelles into a tumor cell. Because micelles remain intact in water, researchers had thought the particles were stable in blood, but Canadian scientists in 2003 showed that the micelles are quickly broken down, releasing the drug into the blood. "The reason is very simple,” Dr. Cheng said. "Unlike water, blood has many components like surfactants and lipids and proteins that interact with the whole micelle structure. As a result, the micelles are unstable in blood and the drug is released too soon.”

The Purdue researchers evaluated how stable micelles are in different blood components. Findings indicated that the micelles remained intact in red blood cells and components of blood plasma except for a class of plasma proteins called alpha and beta globulins, which caused the drug to be released. "There could also be other blood components that cause the drug to be released, but our proposal of using crosslinking could prevent this from happening,” Dr. Cheng said.

Future study, according to the researchers, may concentrate on creating micelles that remain intact longer in the blood by using crosslinking.


Related Links:
Purdue University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.